Analysis of Association of 174 G/C Interleukin 6 Polymorphism and Therapeutic Response to Methotrexate in Rheumatoid Arthritis
Sažetak
Introduction: Rheumatoid arthritis (RA) is a systemic autoimmune disease with IL-6 as a main mediator of systemic and localized inflammation. The most often used drug for the treatment of RA is methotrexate (MTX).
Objective: To explore is there an association between the 174G/C polymorphism in IL6 gene and response to methotrexate therapy in RA patients.
Materials and Method: Study has included 131 RA patients treated and followed at the Institute of Rheumatology, School of Medicine, University of Belgrade. Clinical response to the MTX therapy was conducted following the EULAR response criteria. DNA of each patient was isolated by salting-out method. For each patient IL6 174G/C polymorphism genotype was determined by allele specific PCR method. For statistical analyses we have used SPSS program version 17.0.
Results: According to EULAR response criteria 103 (78.6%) patients were responders (12 (9.2%) good and 91 (69.5%) moderate response) and 28 (21.4%) were non responders. Among all patients in 47 (35.9%) we have detected GG genotype, in 69 (52.7%) GC genotype and in 15 (11.5%) CC genotype. We have observed no association between genotypes or alleles and response to MTX therapy.
Conclusion: No association of -174G/C IL-6 polymorphism and therapeutic response to MTX in RA patients in Serbian population was observed.
Reference
Arthritis Foundation. What is Rheumatoid Arthritis?. Arthritis Foundation. 2018, March 01.
S. A. Zavaleta-Muñiz, B. T.-M.-L. The −174G/C and −572G/C Interleukin 6 Promoter Gene Polymorphisms in Mexican Patients with Rheumatoid Arthritis: A Case-Control Study. Clinical and Developmental Immunology. (2013).
J. Eskdale, G. G. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Journal of Biological Chemistry. 1998.
C. F. Terry, V. L. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. Journal of Biological Chemistry. (2000); 18138-1814.
D. Fishman, G. F. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. Journal of Clinical Investigation. 1998; 1369-1376.
Web MD. How Does Methotrexate Treat Rheumatoid Arthritis? Web MD. 2016.
Canadian Institutes of Health Research, Alberta Innovates-Health Solutions, The Metabolomics Innovation Centre. Methotrexate. Drugbank. 2018, March 01.
Universtiy of Kanasa Medical Center. Methotrexate. Medscape. 2012.
Arnett FC, Edworthy SM, Bloch DA. The American Rheumatism Association 987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31:315–324.
Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LD, van Riel PL. Modified disease-activity scores that include 28-joint counts. development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38:44–48.
Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol. 2005; 93–99
Maced J Med Sci. Assessment of the -174G/C (rs1800795). Epub. 2016 Dec 15.
Amr K, El-Awady R, Raslan H1. -572G/C Interleukin 6 Gene Polymorphisms in Egyptian Patients with Rheumatoid Arthritis. Epub. 2016 Oct 11.
.You CG, Li XJ, Li YM, Wang LP, Li FF, Guo XL, Gao LN. Association analysis of single nucleotide polymorphisms of proinflammatory cytokine and their receptors genes with rheumatoid arthritis in northwest Chinese Han population. Epub. 2012 Nov 11.
Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Gawronska-Szklarz B. Association of cytokine gene polymorphisms and the release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. Epub. 2005 Sep 6.
Marwa OS, Kalthoum T, Wajih K, Kamel H. Association of IL17A and IL17F genes with rheumatoid arthritis disease and the impact of geneticpolymorphisms on response to treatment. Epub. 2017 Jan 28